JP2018502572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502572A5 JP2018502572A5 JP2017534345A JP2017534345A JP2018502572A5 JP 2018502572 A5 JP2018502572 A5 JP 2018502572A5 JP 2017534345 A JP2017534345 A JP 2017534345A JP 2017534345 A JP2017534345 A JP 2017534345A JP 2018502572 A5 JP2018502572 A5 JP 2018502572A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- bispecific antibody
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562099236P | 2015-01-02 | 2015-01-02 | |
| US62/099,236 | 2015-01-02 | ||
| US201562200363P | 2015-08-03 | 2015-08-03 | |
| US62/200,363 | 2015-08-03 | ||
| US201562261609P | 2015-12-01 | 2015-12-01 | |
| US62/261,609 | 2015-12-01 | ||
| PCT/US2015/068238 WO2016109774A1 (en) | 2015-01-02 | 2015-12-31 | Bispecific antibodies against plasma kallikrein and factor xii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020128994A Division JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502572A JP2018502572A (ja) | 2018-02-01 |
| JP2018502572A5 true JP2018502572A5 (enExample) | 2019-02-14 |
| JP6744313B2 JP6744313B2 (ja) | 2020-08-26 |
Family
ID=56285069
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534345A Active JP6744313B2 (ja) | 2015-01-02 | 2015-12-31 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2020128994A Active JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2021150755A Active JP7241827B2 (ja) | 2015-01-02 | 2021-09-16 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2023035060A Active JP7635285B2 (ja) | 2015-01-02 | 2023-03-07 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020128994A Active JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2021150755A Active JP7241827B2 (ja) | 2015-01-02 | 2021-09-16 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2023035060A Active JP7635285B2 (ja) | 2015-01-02 | 2023-03-07 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11390687B2 (enExample) |
| EP (2) | EP3240570B1 (enExample) |
| JP (4) | JP6744313B2 (enExample) |
| KR (2) | KR102670705B1 (enExample) |
| CN (2) | CN114316061B (enExample) |
| AU (2) | AU2015373910B2 (enExample) |
| CA (1) | CA2972800A1 (enExample) |
| CO (1) | CO2017007123A2 (enExample) |
| EA (1) | EA201791527A1 (enExample) |
| IL (2) | IL253180B2 (enExample) |
| MX (2) | MX2017008541A (enExample) |
| NZ (1) | NZ771568A (enExample) |
| WO (1) | WO2016109774A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL253180B2 (en) | 2015-01-02 | 2023-04-01 | Dyax Corp | Bispecific antibodies against plasma kallikrein and factor xii |
| KR102794955B1 (ko) * | 2015-07-21 | 2025-04-15 | 다케다 파머수티컬 컴패니 리미티드 | Xiia 인자의 단일클론 항체 저해제 |
| JP7319916B2 (ja) * | 2016-09-16 | 2023-08-02 | 武田薬品工業株式会社 | 遺伝性血管性浮腫のｒｎａバイオマーカー |
| EP4491234A3 (en) | 2017-02-08 | 2025-04-09 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| BR112019017197A2 (pt) | 2017-02-20 | 2020-04-14 | Dragonfly Therapeutics, Inc. | proteínas que se ligam a her2, nkg2d e cd16 |
| KR20200037388A (ko) * | 2017-08-16 | 2020-04-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16, 및 egfr, hla-e, ccr4 또는 pd-l1에 결합하는 단백질 |
| CN111727201A (zh) * | 2017-10-18 | 2020-09-29 | 再生生物股份有限公司 | 完全人源翻译后修饰的抗体治疗剂 |
| WO2019140320A1 (en) * | 2018-01-12 | 2019-07-18 | Genzyme Corporation | Methods for the quantitation of polypeptides |
| AU2019218125B2 (en) | 2018-02-08 | 2025-03-13 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| PE20220278A1 (es) | 2018-02-08 | 2022-02-25 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d |
| TW201942134A (zh) | 2018-02-20 | 2019-11-01 | 美商蜻蜓醫療公司 | 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法 |
| KR20210025046A (ko) * | 2018-06-08 | 2021-03-08 | 가부시키가이샤 모달리스 | 개변된 Cas9 단백질 및 그의 용도 |
| AU2019299935A1 (en) * | 2018-07-11 | 2021-02-18 | Inc. Momenta Pharmaceuticals | Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to PD-L1 |
| CN112789291A (zh) * | 2018-08-08 | 2021-05-11 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| KR20250112921A (ko) * | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| JP2022512688A (ja) * | 2018-10-24 | 2022-02-07 | シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド | Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用 |
| CN114375302B (zh) * | 2019-07-26 | 2024-12-24 | 詹森生物科技公司 | 包含激肽释放酶相关肽酶2抗原结合结构域的蛋白质及其用途 |
| EP4146271A4 (en) | 2020-05-06 | 2024-09-04 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A |
| EP4236974A2 (en) * | 2020-10-29 | 2023-09-06 | RegenxBio Inc. | Vectorized factor xii antibodies and administration thereof |
| WO2022156798A1 (zh) * | 2021-01-25 | 2022-07-28 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| WO2022156799A1 (zh) * | 2021-01-25 | 2022-07-28 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| US12377144B2 (en) | 2021-03-03 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen |
| CN115925967A (zh) * | 2021-04-22 | 2023-04-07 | 广东菲鹏制药股份有限公司 | 双特异性多功能融合多肽 |
| WO2024238407A2 (en) * | 2023-05-12 | 2024-11-21 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of treating dilated cardiomyopathy and heart failure |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
| US5500349A (en) | 1989-01-27 | 1996-03-19 | Coagen Limited | Blood-coagulation factor XIIA β monoclonal antibody and immunoassay |
| ATE240401T1 (de) | 1989-03-21 | 2003-05-15 | Vical Inc | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0487587A1 (en) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| EP0534988A1 (en) | 1990-05-10 | 1993-04-07 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
| AU663725B2 (en) | 1991-08-20 | 1995-10-19 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| US6093399A (en) * | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| ATE227979T1 (de) | 1993-04-22 | 2002-12-15 | Skyepharma Inc | Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| EP0694070B1 (en) | 1993-09-15 | 2002-04-10 | Chiron Corporation | Recombinant alphavirus vectors |
| SK283703B6 (sk) | 1993-10-25 | 2003-12-02 | Canji, Inc. | Rekombinantný adenovírusový vektor a jeho použitie |
| DK0729351T3 (da) | 1993-11-16 | 2000-10-16 | Skyepharma Inc | Vesikler med reguleret afgivelse af aktivstoffer |
| JP4303315B2 (ja) | 1994-05-09 | 2009-07-29 | オックスフォード バイオメディカ（ユーケー）リミテッド | 非交差性レトロウイルスベクター |
| AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| GB9609262D0 (en) | 1996-05-02 | 1996-07-03 | Isis Innovation | Peptide library and method |
| DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
| CA2364484A1 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| CN101260156A (zh) * | 2002-06-28 | 2008-09-10 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| JP5118492B2 (ja) | 2004-12-23 | 2013-01-16 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 血栓の形成の防止および／または安定化の防止 |
| GB0500487D0 (en) | 2005-01-11 | 2005-02-16 | Axis Shield Diagnostics Ltd | Forms of factor XIIa |
| US7932021B2 (en) | 2005-07-28 | 2011-04-26 | American Diagnostica, Inc. | Lupus anticoagulant testing |
| GB0607515D0 (en) | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| TWI496582B (zh) * | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| TR201904662T4 (tr) | 2008-12-18 | 2019-05-21 | Gruber Andras | Anti-fxı antikorları ve kullanma yöntemleri. |
| RS62853B1 (sr) | 2010-01-06 | 2022-02-28 | Takeda Pharmaceuticals Co | Proteini koji vezuju kalikrein plazme |
| JP6013915B2 (ja) | 2010-11-17 | 2016-10-25 | 中外製薬株式会社 | 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子 |
| AU2012204202A1 (en) | 2011-01-06 | 2013-07-11 | Dyax Corp. | Plasma kallikrein binding proteins |
| FI2734552T3 (fi) * | 2011-07-22 | 2025-02-12 | Csl Behring Gmbh | Monoklonaaliset anti-tekijä xii/xiia -vasta-aineet ja niiden käyttö |
| EP2548892A1 (en) | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
| JP5653860B2 (ja) | 2011-07-28 | 2015-01-14 | 富士フイルム株式会社 | 管壁の硬度測定方法および装置 |
| JP6271251B2 (ja) * | 2011-10-05 | 2018-01-31 | 中外製薬株式会社 | 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子 |
| HRP20201004T1 (hr) * | 2011-12-20 | 2020-10-16 | Medimmune, Llc | Modificirani polipeptidi za skelete bispecifičnog protutijela |
| EP2623110A1 (en) * | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| EP2847228B1 (en) | 2012-05-10 | 2018-07-25 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| WO2014019644A1 (en) * | 2012-07-31 | 2014-02-06 | Baxter International Inc. | Selective measurement of active human protease coagulation factors |
| US9574013B2 (en) | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
| HRP20190528T1 (hr) * | 2013-01-20 | 2019-05-17 | Dyax Corp. | PROCJENA, TESTOVI I LIJEČENJE POREMEĆAJA POSREDOVANIH S pKAL |
| CA3208188A1 (en) | 2013-03-15 | 2014-09-25 | Takeda Pharmaceutical Company Limited | Anti-plasma kallikrein antibodies |
| US20160166660A1 (en) * | 2013-06-28 | 2016-06-16 | Csl Behring Gmbh | Combination therapy using a factor xii inhibitor and a c-1 inhibitor |
| DK3406633T3 (da) | 2013-07-25 | 2022-03-28 | Cytomx Therapeutics Inc | Multispecifikke antistoffer, multispecifikke aktiverbare antistoffer og fremgangsmåder til anvendelse heraf |
| IL253180B2 (en) | 2015-01-02 | 2023-04-01 | Dyax Corp | Bispecific antibodies against plasma kallikrein and factor xii |
| KR102794955B1 (ko) | 2015-07-21 | 2025-04-15 | 다케다 파머수티컬 컴패니 리미티드 | Xiia 인자의 단일클론 항체 저해제 |
| EP3263803B1 (en) | 2016-06-30 | 2019-08-14 | ABB Schweiz AG | Substation |
-
2015
- 2015-12-31 IL IL253180A patent/IL253180B2/en unknown
- 2015-12-31 CN CN202210054884.3A patent/CN114316061B/zh active Active
- 2015-12-31 US US15/541,066 patent/US11390687B2/en active Active
- 2015-12-31 EP EP15876336.7A patent/EP3240570B1/en active Active
- 2015-12-31 IL IL298086A patent/IL298086B2/en unknown
- 2015-12-31 CN CN201580075633.1A patent/CN107405399B/zh active Active
- 2015-12-31 CA CA2972800A patent/CA2972800A1/en active Pending
- 2015-12-31 EA EA201791527A patent/EA201791527A1/ru unknown
- 2015-12-31 EP EP25204079.5A patent/EP4670785A2/en active Pending
- 2015-12-31 MX MX2017008541A patent/MX2017008541A/es unknown
- 2015-12-31 JP JP2017534345A patent/JP6744313B2/ja active Active
- 2015-12-31 WO PCT/US2015/068238 patent/WO2016109774A1/en not_active Ceased
- 2015-12-31 NZ NZ771568A patent/NZ771568A/en unknown
- 2015-12-31 KR KR1020177021610A patent/KR102670705B1/ko active Active
- 2015-12-31 AU AU2015373910A patent/AU2015373910B2/en active Active
- 2015-12-31 KR KR1020247017566A patent/KR20240091031A/ko active Pending
-
2017
- 2017-06-26 MX MX2024000317A patent/MX2024000317A/es unknown
- 2017-07-17 CO CONC2017/0007123A patent/CO2017007123A2/es unknown
-
2020
- 2020-07-30 JP JP2020128994A patent/JP7003347B2/ja active Active
-
2021
- 2021-09-16 JP JP2021150755A patent/JP7241827B2/ja active Active
-
2022
- 2022-02-17 AU AU2022201076A patent/AU2022201076B2/en active Active
- 2022-06-13 US US17/838,769 patent/US12240918B2/en active Active
-
2023
- 2023-03-07 JP JP2023035060A patent/JP7635285B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502572A5 (enExample) | ||
| JP2020186248A5 (enExample) | ||
| CN106459220B (zh) | 适用于高通量筛选的新的双特异性形式 | |
| US11286312B2 (en) | Multispecific antibodies | |
| JP2016533174A5 (enExample) | ||
| KR102282691B1 (ko) | 개변된 헬퍼 파지를 사용하여 항원 결합 분자를 제작하는 방법 | |
| JP7203800B2 (ja) | ヌクレオチド・ライブラリー | |
| JP7549961B2 (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| JP2017512063A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| JP2017509335A5 (enExample) | ||
| JP2020500510A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| JP2014521313A5 (enExample) | ||
| JP2018512124A5 (enExample) | ||
| KR20190111946A (ko) | 1가 항-프로페르딘 항체 및 항체 단편 | |
| JP2019506839A5 (enExample) | ||
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью | |
| CN111526887A (zh) | 用于使血清中的蛋白质半衰期增加的组合物和方法 | |
| CN104955846B (zh) | 人源化抗hmgb1抗体或其抗原结合性片段 | |
| Henry et al. | A disulfide-stabilized human VL single-domain antibody library is a source of soluble and highly thermostable binders | |
| Aoki et al. | Engineering a low-immunogenic mirror-image VHH against vascular endothelial growth factor | |
| CN107073093A (zh) | 亲和蛋白及其用途 | |
| CA3218571A1 (en) | Methods of screening and expression of disulfide-bonded binding polypeptides |